A share price of Contineum Therapeutics Inc [CTNM] is currently trading at $10.01, up 2.14%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CTNM shares have gain 12.85% over the last week, with a monthly amount glided 92.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Robert W. Baird started tracking the stock with Outperform rating on October 22, 2024, and set its price target to $32. On April 30, 2024, Stifel initiated with a Buy rating and assigned a price target of $29 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $30 on April 30, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $25 as its price target on April 30, 2024.
Contineum Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.35 and $20.32. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Contineum Therapeutics Inc [NASDAQ: CTNM] shares were valued at $10.01 at the most recent close of the market. An investor can expect a potential return of 59.84% based on the average CTNM price forecast.
Analyzing the CTNM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.3 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.47 points at the first support level, and at 8.93 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.40, and for the 2nd resistance point, it is at 10.80.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Contineum Therapeutics Inc [NASDAQ:CTNM] is 24.51. As well, the Quick Ratio is 24.51, while the Cash Ratio is 2.88.
Transactions by insiders
Recent insider trading involved Lorrain Daniel S., Chief Scientific Officer, that happened on Nov 25 ’24 when 1010.0 shares were sold. Chief Scientific Officer, Lorrain Daniel S. completed a deal on Nov 18 ’24 to sell 6190.0 shares. Meanwhile, Officer DANIEL LORRAIN bought 26370.0 shares on Nov 18 ’24.
